Bringing you live news and features since 2006 

ETFMG adds biotech fund to thematic ETF offering


Thematic ETF issuer ETFMG has launched the ETFMG Treatments, Testing and Advancements ETF (GERM), which seeks to answer investor demand for direct exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. The first-to-market methodology behind the Fund focuses on the advancements in the infectious disease sub-sector of biotech with targeted exposure to US-listed companies at the forefront of R&D, vaccines, therapies and testing technologies.

GERM provides access to both established providers as well as the “unsung heroes” of the biotech and life sciences market. The frequency and diversity of disease outbreaks, similar to COVID-19, have grown steadily for the past 30 years.

“Our global health depends a great deal on innovation and discovery that will address how to prevent further infection with enhanced immune therapies or vaccines,” says Reynold A Panettieri, Jr, MD, Professor of Medicine, Vice Chancellor for Translational Medicine and Science at Rutgers University, and Director of the Institute for Translational Medicine and Science. “GERM offers a unique approach that embraces cutting-edge technologies through cooperativity among Big/Small Pharma and biotech that can nimbly leverage discoveries and translate them into commercialised and impactful assets.”

“GERM represents an investment theme that is much more than topical, it provides unique exposure to a previously underrepresented growth sector within biotech. We are excited to bring this product to US investors,” says Sam Masucci, CEO and Founder of ETFMG.

Latest News

Solactive writes that in the face of market volatility, investors often turn to portfolio diversification as a key strategy. “One..
The Luxembourg House of Financial Technology (LHoFT), together with PwC Luxembourg and with the active support of the Association of..
Sustainability tech platform Clarity AI has announced that its sustainability capabilities are now supporting European white label platform, HANetf...
Chimera Capital LLC, an Abu-Dhabi-based investment management firm, has announced the launch of the Chimera S&P China HK Shariah Exchange..

Related Articles

Henry Timmons, RBA
Henry Timmons, director of ETFs and Michael Contopoulos, director of fixed income at Richard Bernstein Advisors are on a mission...
Kelsey Mowrey, Motley Fool Asset Management
Speaking with ETF Express in March, Brian Barish, a fund manager with Cambiar commented on the Vanguard solution which allows...
Phillippe Malaise, Trackinsight
Trackinsight has published its fourth global ETF survey, revealing that investors have an appetite for actively managed ETFs....
Joy Yang, MVIS
The passive versus active debate is a ‘thought experiment’ according to Joy Yang, Head of Index Product Management at MarketVector...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by